Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released
Fri, 30 Jul 2010 05:37:51 -0700
Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE (bortezomib) in patients with relapsed/refractory mantle cell lymphoma. The data, derived from an analysis of archived tumor samples, tested pre-specified biomarkers for their association with time to progression and response to treatment with VELCADE in patients with ...
Read More...
